Elizabeth Bilotti

发表

Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.

D. Siegel, D. Vesole, A. McNeill, 2012, Clinical lymphoma, myeloma & leukemia.

Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board.

Joseph D Tariman, J. Tariman, Sandra I Rome, 2011, Clinical journal of oncology nursing.

Routine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

C. Gleason, A. McNeill, E. Bilotti, 2011, Clinical journal of oncology nursing.

Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

B. Faiman, E. Bilotti, P. Mangan, 2008, Clinical journal of oncology nursing.

A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens

D. Siegel, D. Vesole, L. Sanchez, 2017, British journal of haematology.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Jeffrey A Jones, J. Byrd, N. Heerema, 2015, Blood.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

N. Munshi, J. Laubach, P. Richardson, 2013, Blood.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

M. Dimopoulos, C. Buske, S. Treon, 2017, The Lancet. Oncology.

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

D. Siegel, D. Vesole, A. Mato, 2015, British journal of haematology.

Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.

Jeffrey A Jones, J. Byrd, I. Flinn, 2014 .

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

D. Siegel, D. Vesole, J. Richter, 2011 .

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)

M. Dimopoulos, C. Buske, S. Treon, 2015 .

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.

D. Siegel, D. Vesole, A. Mato, 2016, Clinical lymphoma, myeloma & leukemia.

Routine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

C. Gleason, A. McNeill, Elizabeth Bilotti, 2011, Clinical journal of oncology nursing.

New Directions in the Treatment of Multiple Myeloma

E. Bilotti, Elizabeth Bilotti, 2012 .

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents

S. Kurtin, E. Bilotti, Elizabeth Bilotti, 2013, Journal of the advanced practitioner in oncology.

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeffrey A Jones, J. Byrd, I. Flinn, 2017, Clinical Cancer Research.

Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies Serum Free Light Chain Analysis Provides a More Accurate Measure of Light Chain Burden Than Urine Protein Electrophoresis

D. Siegel, A. McNeill, N. Lendvai, 2009 .

Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia

R. Furman, T. Graef, E. Bilotti, 2017, Leukemia & lymphoma.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

M. Dimopoulos, C. Buske, R. Hájek, 2018, The Lancet. Haematology.

The anion gap and routine serum protein measurements in monoclonal gammopathies.

D. Siegel, A. McNeill, W. J. Gaughan, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Serum Free Light Chain Analysis for Diagnosis, Monitoring, and Prognosis of Monoclonal Gammopathies

D. Siegel, E. Bilotti, K. H. Hoeven, 2009 .

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

Michael L. Wang, D. Siegel, R. Vij, 2012 .

Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board.

Joseph D Tariman, Sandra I Rome, B. Faiman, 2011, Clinical journal of oncology nursing.

bortezomib with refractory multiple myeloma who have received lenalidomide and Phase 1 study of pomalidomide MTD, safety, and efficacy in patients

D. Siegel, N. Munshi, J. Laubach, 2013 .